 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...1819202122232425262728...100101» |
- |||| Enrollment open, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=148, Recruiting, Sponsor: Gynaecologisch Oncologisch Centrum Zuid
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2025 --> Oct 2026
- ||||| giredestrant (GDC-9545) / Roche
Enrollment closed: A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) (clinicaltrials.gov) - Apr 18, 2023
P3, N=992, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2025 --> Oct 2026 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer. (Pubmed Central) - Apr 18, 2023
via GPR30-AKT signaling. CYP19A1 inhibition combined with PD-1 blockade represents a promising therapeutic strategy for colon cancer immunotherapy.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Journal, Metastases: Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis. (Pubmed Central) - Apr 17, 2023
No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.
- | tamoxifen / Generic mfg.
Journal: Unilateral Tamoxifen-Induced Retinopathy as a Consequence of Breast Cancer Treatment-Multimodal Imaging Value. (Pubmed Central) - Apr 13, 2023
The patient attends ophthalmological examination regularly. Visual acuity, OCT and OCTA results remain stable.
- | letrozole / Generic mfg.
Retrospective data, Journal: Corifolitropin-Alfa plus Five Days Letrozole Versus Daily Recombinant-FSH in Expected Normo-Responder Patients: A Retrospective Comparative Study. (Pubmed Central) - Apr 13, 2023
Moreover, the experimental protocol resulted in lower estradiol and progesterone values at ovulation induction compared to daily rFSH, with an increased chance of performing a fresh embryo transfer (with no OHSS occurrence). Given the observational design of our study, further well-conducted RCTs are needed.
- Keytruda (pembrolizumab) / Merck (MSD), Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
CDK 4/6 inhibitors induced liver injury: 7 cases from REFHEPS registry (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_954;
A few DILI cases have been reported in the literature. The mechanism of toxicity is unknown.
- | letrozole / Generic mfg.
Trial completion date: Letrozole in Patients With Hepatopulmonary Syndrome (clinicaltrials.gov) - Apr 12, 2023
P2, N=20, Recruiting, Sponsor: Mayo Clinic
The mechanism of toxicity is unknown. Trial completion date: Dec 2024 --> Dec 2023
- |||| Biomarker, New P4 trial: Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy (clinicaltrials.gov) - Apr 12, 2023
P4, N=100, Recruiting, Sponsor: Yongsheng Wang
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical: More on the results of @GOG 3026 presented at #SGO2023 meeting by @GynCancerMD. #Ribociclib and #letrozole in patients with recurrent low-grade serous #ovariancancer. From @ecancer. @kisqali_us #SGOmtg #LGSOC #clinicaltrial #gync…https://t.co/bAmUWJVLI2 https://t.co/ijJjW6Yero (Twitter) - Apr 10, 2023
- | letrozole / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date: Letrozole in Tubal Ectopic Pregnancy (clinicaltrials.gov) - Apr 10, 2023
P3, N=214, Recruiting, Sponsor: Queen Mary Hospital, Hong Kong
Trial completion date: Dec 2024 --> Dec 2023 Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Dec 2024
- ||| Ibrance (palbociclib) / Pfizer
Trial completion, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Apr 7, 2023
P2, N=55, Completed, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting | Trial completion date: Jun 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Dec 2024 Active, not recruiting --> Completed
- ||| Biomarker, Enrollment change, Trial completion date: BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (clinicaltrials.gov) - Apr 6, 2023
P2, N=550, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=400 --> 550 | Trial completion date: Mar 2026 --> Sep 2026
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer (clinicaltrials.gov) - Apr 6, 2023
P2, N=30, Recruiting, Sponsor: Yantai Yuhuangding Hospital
- | letrozole / Generic mfg., celecoxib oral / Generic mfg.
Journal: Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities. (Pubmed Central) - Apr 5, 2023
N=400 --> 550 | Trial completion date: Mar 2026 --> Sep 2026 Compounds 10c, 11a, 11e were more selective for COX-2 isozyme (S.I.
- | New trial: NEMO: Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia (clinicaltrials.gov) - Apr 5, 2023
P=N/A, N=300, Recruiting, Sponsor: Blokhin's Russian Cancer Research Center
- ||| narazaciclib (HX301) / Traws Pharma
Enrollment open, Combination therapy, Metastases: Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies (clinicaltrials.gov) - Apr 5, 2023
P1/2, N=60, Recruiting, Sponsor: Onconova Therapeutics, Inc.
Compounds 10c, 11a, 11e were more selective for COX-2 isozyme (S.I. Not yet recruiting --> Recruiting
- Ibrance (palbociclib) / Pfizer
PALBOCICLIB: ADDED VALUE OF LONG-TERM EFFICACY, SAFETY AND REAL-WORLD DATA (RM 1 (Vista 1+2)) - Apr 4, 2023 - Abstract #GBCC2023GBCC_17;
Not yet recruiting --> Recruiting PALOMA-3 trial also showed Palbociclib
- || Piqray (alpelisib) / Novartis
Trial completion date, Metastases: BYLieve: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (clinicaltrials.gov) - Apr 4, 2023
P2, N=383, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
PALOMA-3 trial also showed Palbociclib Trial completion date: Jul 2023 --> Jul 2025
- ||| atirmociclib (PF-07220060) / Pfizer
Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: C4391001: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov) - Mar 31, 2023
P1/2, N=337, Recruiting, Sponsor: Pfizer
Trial completion date: Jul 2023 --> Jul 2025 Phase classification: P1 --> P1/2 | N=118 --> 337 | Trial completion date: Apr 2025 --> Feb 2026 | Trial primary completion date: Apr 2025 --> Feb 2026
- ||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P1/2 trial, Metastases: SHR-A1811-206: A Phase ?b/? Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer. (clinicaltrials.gov) - Mar 31, 2023
P1/2, N=300, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | letrozole / Generic mfg.
Preclinical, Journal: Protective effect of wuzibushen recipe on follicular development via regulating androgen receptor in polycystic ovary syndrome model rats. (Pubmed Central) - Mar 29, 2023
Moreover, WZBS recipe decreased serum T content, AR expression and increased serum SHBG content, CX43 expression in PCOS rats. This study reveals that WZBS recipe may attenuate PCOS by protecting follicular development via down-regulating AR.
- ||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
More on the results of @GOG 3026 presented at #SGOmtg by Dr. @GynCancerMD. #Ribociclib & #Letrozole in #Recurrent low grade serous #OvarianCancer. From @CancerTherAdvsr @GynCancerMD #GYNCSM @kisqali_us #SGO2023 (Twitter) - Mar 29, 2023
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Trial completion date, Metastases: RibOB: A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (clinicaltrials.gov) - Mar 29, 2023
P=N/A, N=78, Active, not recruiting, Sponsor: Universitaire Ziekenhuizen KU Leuven
This study reveals that WZBS recipe may attenuate PCOS by protecting follicular development via down-regulating AR. Recruiting --> Active, not recruiting | N=150 --> 78 | Trial completion date: Dec 2022 --> Dec 2023
- ||| letrozole / Generic mfg.
Trial completion, Enrollment change: SMART Protocol vs Antagonist Protocol in IVF (clinicaltrials.gov) - Mar 29, 2023
P=N/A, N=426, Completed, Sponsor: Clinique Ovo
Recruiting --> Active, not recruiting | N=150 --> 78 | Trial completion date: Dec 2022 --> Dec 2023 Active, not recruiting --> Completed | N=3600 --> 426
- | letrozole / Generic mfg.
Preclinical, Journal: Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines. (Pubmed Central) - Mar 28, 2023
This in vitro study demonstrated that treatment of testosterone proliferating cells with letrozole resulted in decreased prolactin levels and cell proliferation and induced apoptosis, and further loss of aromatase and Esr1 mRNA expression were observed. Although this is an in vivo study, the results showed unique and novel findings which may easily be adapted to clinical use for further verification.
- | metformin / Generic mfg., letrozole / Generic mfg., pioglitazone / Generic mfg.
Journal: Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4?. (Pubmed Central) - Mar 27, 2023
Our findings hint at the value of HNF-4? in the treatment of PCOS by PIO, which could shed light on potential targets that may be used in treatments for PCOS with metabolic disorders.
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Trial completion date: NSABP B-42: Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Mar 27, 2023
P3, N=3966, Active, not recruiting, Sponsor: NSABP Foundation Inc
in the treatment of PCOS by PIO, which could shed light on potential targets that may be used in treatments for PCOS with metabolic disorders. Trial completion date: Dec 2022 --> Dec 2023
- |||| letrozole / Generic mfg., carboplatin / Generic mfg., paclitaxel / Generic mfg.
Thanks to @amandanfader, of @HopkinsMedicine, for stopping by during #SGOMtg to discuss a study of paclitaxel, carboplatin, and letrozole in serous carcinoma of the ovary or peritoneum! See our site for more from the meeting! @SGO_org #gyncsm https://t.co/nzXu3EkUq2 (Twitter) - Mar 26, 2023
- ||||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Clinical: GOG-3026 Ribociclib + Letrozole in Recurrent low-grade serous carcinoma of ovary (LGSOC), 27% patients already had prior hormonal therapy: ORR 23%, CBR 79%, DOR 19.1 months, #SGO_org, #SGOmtg, #SGO23, #PatientsPurposeProgress (Twitter) - Mar 26, 2023
- Ibrance (palbociclib) / Pfizer
A Man With Palbociclib-Induced Pneumonitis: A Very Rare Entity (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_3515;
He was receiving his second cycle of palbociclib along with letrozole, leuprolide and denosumab...He was initially treated for community acquired pneumonia with ceftriaxone and azithromycin...Palbociclib was also discontinued. Bronchoscopy may not always be needed to confirm or excluded other pathology in the appropriate clinical context especially in severe cases.
- letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Impact of Ovulation Induction in a Patient With Lymphangioleiomyomatosis (Walter E. Washington Convention Center, Room 209 A-C (Level 2)) - Mar 25, 2023 - Abstract #ATS2023ATS_3216;
A lower rise in estrogen may explain the lack of lung function decline in our case. With the increasing use of assisted reproductive techniques, research regarding its impact on patients with hormone-sensitive conditions like LAM is needed.
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Head to our site for #SGOMtg updates from @GynCancerMD, of @MountSinaiNYC, who shared key findings with letrozole and ribociclib in serous ovarian carcinoma. Thanks for speaking with us at #SGOMtg, Dr Slomovitz! @SGO_org #gyncsm https://t.co/JNsBQ1OiAw (Twitter) - Mar 25, 2023
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
@GynCancerMD opening plenary at @SGO2023mtg Ribociclib and letrozole active in low grade serous #ovariancancer. Congrats! @SGO_org @GOG @gyncsm @SHAREing @IGCSociety (Twitter) - Mar 24, 2023
- |||| letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Late-breaking abstract: GOG3026. Letrozole + Ribociclib in ovarian LGSOC. Promising early results in one of the more difficult to manage women's cancers. @GynCancerMD presenting late breaking abstract at #sgo2023 #SGOMtg (Twitter) - Mar 24, 2023
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
P2 data, Journal: ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer. (Pubmed Central) - Mar 24, 2023
With the increasing use of assisted reproductive techniques, research regarding its impact on patients with hormone-sensitive conditions like LAM is needed. No abstract available
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
P2 data, Journal: Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. (Pubmed Central) - Mar 24, 2023
However, a significant proportion will have downstaged to allow for BCS. Local-regional recurrence after surgery is uncommon (1.5% at 5
- | Journal: Kinin B and B receptors mediate cancer pain associated with both the tumor and oncology therapy using aromatase inhibitors. (Pubmed Central) - Mar 24, 2023
We investigate the involvement of the kinin B and B receptors in metastatic breast tumor (4T1 breast cancer cells)-caused pain and in aromatase inhibitors (anastrozole or letrozole) therapy-associated pain...Kinin B (DALBk) and B (Icatibant) receptor antagonists attenuated these effects and reduced breast tumor-induced mechanical and cold allodynia...Antagonists did not interfere with paclitaxel's cytotoxic action in vitro. Thus, kinin B or B receptors can be a potential target for treating the pain caused by metastatic breast tumor and their antineoplastic therapy.
- | letrozole / Generic mfg.
Preclinical, Journal: The ameliorative effect of CangFu Daotan Decoction on polycystic ovary syndrome of rodent model is associated with m6A methylation and Wnt/?-catenin pathway. (Pubmed Central) - Mar 24, 2023
CDD reduced the m6A proteins expressions of Mettl3, Fto, and Ythdf1 in the ovarian tissue of PCOS rats. CDD can regulate
- || carotuximab IV (ENV105) / Kairos Pharma
Biomarker, P1/2 data, Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. (Pubmed Central) - Mar 24, 2023
P1/2
Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.
- | Trial completion date, Trial primary completion date: HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. (clinicaltrials.gov) - Mar 24, 2023
P3, N=1294, Active, not recruiting, Sponsor: National Cancer Institute, Naples
Pharmacokinetic studies revealed an interaction between everolimus and carotuximab. Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2021 --> Nov 2024
- || LOXO-783 / Eli Lilly
Enrollment change, Combination therapy, Monotherapy, Metastases: PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) - Mar 24, 2023
P1, N=400, Recruiting, Sponsor: Eli Lilly and Company
Trial completion date: Nov 2022 --> Nov 2024 | Trial primary completion date: Nov 2021 --> Nov 2024 N=300 --> 400
- ||| zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy: RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Mar 23, 2023
P2, N=60, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=300 --> 400 N=40 --> 60 | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2023 --> May 2024
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
The Effect of Hormone Receptor Positive Percentage On Treatment Response And Prognosis In HR+ HER2- Metastatic Breast Cancer Receiving CDK 4/6 Inhibitor + Endocrine Treatment (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_505;
Conclusions In conclusion, to the best of our knowledge, this study showed for the first time in the literature that the percentage of hormone receptor positivity has a predictive and prognostic role in HR+ HER-2 MBC patients who were treated with ET with CDK 4/6 inhibitor. The percentage of HR positivity is also important at these patient.
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative Metastatic Breast Cancer (MBC) treates with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi) (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_504;
LT occurred in 3%, 8% and 11.6% of pts receiving palbociclib, abemaciclib and ribociclib, respectively...Concomitant ET was letrozole 54%, fulvestrant 35% and anastrozole 11%...LT was mainly reversible with no fatal cases. These results could help to develop prediction scores to identify patients at risk of developing severe LT.
- letrozole / Generic mfg.
Correlation of MIB1 Labeling Index and Hormone Receptor Status with Survival in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors and Letrozole (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_500;
Conclusions Real-world data of patients receiving palbociclib or ribociclib in combination with letrozole show that these CDK4/6 inhibitors are more effective in patients with higher ER expression. MIB1 expression also seem to be correlated with mPFS, patients with higher MIB1 have better prognosis, although more research is needed.
- Verzenio (abemaciclib) / Eli Lilly
Abemaciclib for Treating Patients with HR+, HER2- Advanced/Metastatic Breast Cancer in the UK: A Real World Study (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_499;
Conclusions ABE, used in different treatment lines (including later lines in more heavily pretreated patients (?3rd line)) in combination with fulvestrant or AIs, was associated with a median PFS of 21.9 months in a UK real-world setting. These data are comparable to those from clinical trials supporting the benefit of ABE in patients with HR+, HER2- ABC/MBC.
- Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment na (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_458;
P1b
The safety profile of gedatolisib + palbo + LET was similar to palbo + LET. These encouraging results warrant further evaluation of gedatolisib in combination with a CDK4/6i + LET in the front-line setting.
- Kisqali (ribociclib) / Novartis
Correlation of circulating tumor DNA (ctDNA) or Thymidine Kinase activity (TKa) Dynamic Patterns with tumor response in patients (pts) with hormone receptor (HR)+ human epidermal growth factor 2 (HER2) - advanced breast cancer (ABC) on ribociclib (RIB) + letrozole (LET) in BioItaLEE trial (Exhibition area) - Mar 22, 2023 - Abstract #ESMOBC2023ESMO_BC_453;
P3
Our data suggest that insufficient inhibition of TKa at C1D15 may be a surrogate marker for tumor progression. If further confirmed, TKa measurement may be helpful for patients needing a rapid evaluation of tumor response.